RS62801B1 - Aminotriazolopiridini kao inhibitori kinaze - Google Patents

Aminotriazolopiridini kao inhibitori kinaze

Info

Publication number
RS62801B1
RS62801B1 RS20220021A RSP20220021A RS62801B1 RS 62801 B1 RS62801 B1 RS 62801B1 RS 20220021 A RS20220021 A RS 20220021A RS P20220021 A RSP20220021 A RS P20220021A RS 62801 B1 RS62801 B1 RS 62801B1
Authority
RS
Serbia
Prior art keywords
pyridin
triazolo
amino
methyl
carboxamide
Prior art date
Application number
RS20220021A
Other languages
English (en)
Serbian (sr)
Inventor
Junqing Guo
Amy C Hart
John E Macor
Michael E Mertzman
William J Pitts
Steven H Spergel
Scott Hunter Watterson
Murugaiah Subbaiah Murugaiah Andappan
Jie Chen
Carolyn Diane Dzierba
Guanglin Luo
Jianliang Shi
Sing-Yuen Sit
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of RS62801B1 publication Critical patent/RS62801B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20220021A 2017-02-13 2018-02-12 Aminotriazolopiridini kao inhibitori kinaze RS62801B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors
EP18707498.4A EP3580220B1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
RS62801B1 true RS62801B1 (sr) 2022-02-28

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220021A RS62801B1 (sr) 2017-02-13 2018-02-12 Aminotriazolopiridini kao inhibitori kinaze

Country Status (25)

Country Link
US (3) US10913738B2 (cg-RX-API-DMAC7.html)
EP (1) EP3580220B1 (cg-RX-API-DMAC7.html)
JP (1) JP7097373B2 (cg-RX-API-DMAC7.html)
KR (1) KR102549952B1 (cg-RX-API-DMAC7.html)
CN (1) CN110520423B (cg-RX-API-DMAC7.html)
AU (1) AU2018217488B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019016635A2 (cg-RX-API-DMAC7.html)
CA (1) CA3053484A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124978T1 (cg-RX-API-DMAC7.html)
DK (1) DK3580220T3 (cg-RX-API-DMAC7.html)
EA (1) EA039808B1 (cg-RX-API-DMAC7.html)
ES (1) ES2902676T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20212000T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057801T2 (cg-RX-API-DMAC7.html)
IL (1) IL268614B (cg-RX-API-DMAC7.html)
LT (1) LT3580220T (cg-RX-API-DMAC7.html)
MA (1) MA47460A (cg-RX-API-DMAC7.html)
MX (1) MX378515B (cg-RX-API-DMAC7.html)
PL (1) PL3580220T3 (cg-RX-API-DMAC7.html)
PT (1) PT3580220T (cg-RX-API-DMAC7.html)
RS (1) RS62801B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907335UA (cg-RX-API-DMAC7.html)
SI (1) SI3580220T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200001T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018148626A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913738B2 (en) * 2017-02-13 2021-02-09 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
WO2019089442A1 (en) * 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
ES2959399T3 (es) 2018-01-26 2024-02-26 Bristol Myers Squibb Co Aminopirrolotriazinas como inhibidores de cinasa
US12234221B2 (en) 2018-07-09 2025-02-25 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NAV1.8
CA3105748A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
KR102793119B1 (ko) * 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
JP7268921B2 (ja) * 2019-01-25 2023-05-08 北京賽特明強医薬科技有限公司 アミド基架橋複素環式化合物、その組成物および応用
JP7323637B2 (ja) * 2019-03-22 2023-08-08 ▲勁▼方医▲薬▼科技(上海)有限公司 置換複素環式アミド化合物、その調製方法、及びその医薬的使用
AU2020357986A1 (en) 2019-10-03 2022-05-26 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
US20230139111A1 (en) * 2020-02-13 2023-05-04 Genfleet Therapeutics (Shanghai) Inc. Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
US11767310B2 (en) 2021-08-10 2023-09-26 Abbvie Inc. Nicotinamide RIPK1 inhibitors
EP4495119A4 (en) 2022-03-16 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF
CN116574053A (zh) * 2022-06-21 2023-08-11 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
AR133939A1 (es) * 2023-09-27 2025-11-19 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de cinasa
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765825A1 (en) 2004-06-25 2007-03-28 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
BRPI0819606A2 (pt) 2007-11-27 2017-05-09 Cellzome Ltd amino triazóis como inobidores de pi3k
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
EP2393813B1 (en) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
CN105246891A (zh) 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
US20170266199A1 (en) 2014-08-21 2017-09-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
US10709133B2 (en) 2015-11-05 2020-07-14 Sumitomo Chemical Company, Limited Condensed heterocyclic compound
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
WO2018139436A1 (ja) 2017-01-24 2018-08-02 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
US10913738B2 (en) * 2017-02-13 2021-02-09 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
WO2019089442A1 (en) 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
ES2959399T3 (es) 2018-01-26 2024-02-26 Bristol Myers Squibb Co Aminopirrolotriazinas como inhibidores de cinasa
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
SG11201907335UA (en) 2019-09-27
AU2018217488B2 (en) 2021-09-23
KR102549952B1 (ko) 2023-06-29
PT3580220T (pt) 2022-01-03
CA3053484A1 (en) 2018-08-16
MX378515B (es) 2025-03-11
ES2902676T3 (es) 2022-03-29
PL3580220T3 (pl) 2022-02-07
HRP20212000T1 (hr) 2022-04-01
MX2019009555A (es) 2019-10-02
EP3580220B1 (en) 2021-11-17
CN110520423B (zh) 2022-08-23
US12157733B2 (en) 2024-12-03
DK3580220T3 (da) 2022-01-10
JP7097373B2 (ja) 2022-07-07
JP2020507582A (ja) 2020-03-12
LT3580220T (lt) 2021-12-27
IL268614A (en) 2019-10-31
AU2018217488A1 (en) 2019-10-03
US10913738B2 (en) 2021-02-09
EA201991915A1 (ru) 2019-12-30
US20190389859A1 (en) 2019-12-26
WO2018148626A1 (en) 2018-08-16
BR112019016635A2 (pt) 2020-04-07
HUE057801T2 (hu) 2022-06-28
US20250074909A1 (en) 2025-03-06
CN110520423A (zh) 2019-11-29
IL268614B (en) 2021-12-01
KR20190117006A (ko) 2019-10-15
MA47460A (fr) 2019-12-18
EP3580220A1 (en) 2019-12-18
CY1124978T1 (el) 2023-01-05
US20220315580A1 (en) 2022-10-06
EA039808B1 (ru) 2022-03-16
SMT202200001T1 (it) 2022-03-21
SI3580220T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
US12157733B2 (en) Aminotriazolopyridines as kinase inhibitors
EP3704118B1 (en) Aminoimidazopyridazines as kinase inhibitors
US11618753B2 (en) Aminopyrrolotriazines as kinase inhibitors
KR102793119B1 (ko) 키나제 억제제로서의 인다졸 카르복스아미드
EP3849968B1 (en) 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
WO2016100166A1 (en) SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
TW202233614A (zh) 作為激酶抑制劑之三唑并吡啶化合物
KR102906523B1 (ko) 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ
CN119431317A (zh) 一种作为抗病毒的三聚氯氰三取代的胺类衍生物、其制备方法及用途